398 related articles for article (PubMed ID: 12239889)
1. [Diagnostics and drug therapy of multiple sclerosis].
Suomen Neurologinen Yhdistys ry
Duodecim; 2002; 118(13):1411-23. PubMed ID: 12239889
[No Abstract] [Full Text] [Related]
2. Seeing injectable ms therapies differently: they are more similar than different.
Johnson KP; Fox RJ; Arnold DL
Neurology; 2010 Feb; 74(8):702. PubMed ID: 20177129
[No Abstract] [Full Text] [Related]
3. New treatments for multiple sclerosis.
Hutchinson M
Ir Med J; 1996; 89(2):44. PubMed ID: 8682623
[No Abstract] [Full Text] [Related]
4. [Multiple sclerosis].
Itoyama Y
No To Shinkei; 2000 Dec; 52(12):1051-5. PubMed ID: 11193536
[No Abstract] [Full Text] [Related]
5. [Drug therapy of multiple sclerosis].
Kinnunen E
Duodecim; 1999; 115(4):403-7. PubMed ID: 11830889
[No Abstract] [Full Text] [Related]
6. Current disease-modifying therapies in multiple sclerosis.
Kieseier BC; Hartung HP
Semin Neurol; 2003 Jun; 23(2):133-46. PubMed ID: 12894379
[TBL] [Abstract][Full Text] [Related]
7. Glatiramer and suspected multiple sclerosis. No proven advantage.
Prescrire Int; 2010 Aug; 19(108):160. PubMed ID: 20941852
[No Abstract] [Full Text] [Related]
8. The effect of glatiramer acetate treatment on pre-existing headaches in patients with MS.
Pöllmann W; Erasmus LP; Feneberg W; Straube A
Neurology; 2006 Jan; 66(2):275-7. PubMed ID: 16434675
[TBL] [Abstract][Full Text] [Related]
9. [New therapeutic methods in the treatment of multiple sclerosis].
Nervenarzt; 1996 Nov; 67(11 Suppl Neue Ther):1-12. PubMed ID: 9402424
[No Abstract] [Full Text] [Related]
10. Disease-modifying drugs for the early treatment of multiple sclerosis.
Flachenecker P
Expert Rev Neurother; 2004 May; 4(3):455-63. PubMed ID: 15853542
[TBL] [Abstract][Full Text] [Related]
11. Patient and family fact sheet. Current treatments for multiple sclerosis.
Kernich CA
Neurologist; 2005 Mar; 11(2):137-8. PubMed ID: 15733335
[No Abstract] [Full Text] [Related]
12. Biogen wins Euro MS approval, but loses patents.
Brower V
Nat Biotechnol; 1997 May; 15(5):410. PubMed ID: 9131611
[No Abstract] [Full Text] [Related]
13. 'Time is brain' also in multiple sclerosis.
Freedman MS
Mult Scler; 2009 Oct; 15(10):1133-4. PubMed ID: 19808740
[No Abstract] [Full Text] [Related]
14. The value of economic modeling studies in the evaluation of treatment strategies for multiple sclerosis.
Detournay B
Value Health; 2002; 5(1):1-2. PubMed ID: 11873378
[No Abstract] [Full Text] [Related]
15. [Clinical surveillance of patients with multiple sclerosis].
Cazzato G; Zorzon M
Recenti Prog Med; 2003 Apr; 94(4):173-6. PubMed ID: 12677789
[TBL] [Abstract][Full Text] [Related]
16. Update on MS treatment.
Ryan M
J Am Pharm Assoc (Wash); 1996 Jul; NS36(7):419-20. PubMed ID: 8840740
[No Abstract] [Full Text] [Related]
17. [Therapy of multiple sclerosis].
Simó M
Neuropsychopharmacol Hung; 2009 Mar; 11(1):23-6. PubMed ID: 19731815
[TBL] [Abstract][Full Text] [Related]
18. The use of interferon beta at the time of initial diagnosis of multiple sclerosis.
Pender MP
J Clin Neurosci; 2001 Jul; 8(4):381-2. PubMed ID: 11437589
[No Abstract] [Full Text] [Related]
19. Should all patients with an initial diagnosis of multiple sclerosis be treated with beta interferon?
Hodgkinson SJ
J Clin Neurosci; 2001 Jul; 8(4):378-9. PubMed ID: 11437587
[No Abstract] [Full Text] [Related]
20. Should all patients with an initial diagnosis of multiple sclerosis be treated with beta interferon? The case against.
Macdonell R
J Clin Neurosci; 2001 Jul; 8(4):379-81. PubMed ID: 11437588
[No Abstract] [Full Text] [Related]
[Next] [New Search]
